Ophthalmic Antihistamine Step Therapy Program Summary
|
|
- Sydney Potter
- 5 years ago
- Views:
Transcription
1 Ophthalmic Antihistamine Step Therapy Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-8 Drug FDA Indication(s) Administration and Dosing Bepreve Treatment of itching associated Instill one drop into the affected (bepotastine) with allergic eye(s) twice a day. 1.5% ophthalmic solution Elestat (epinastine) a 0.05% ophthalmic solution a Emadine (emedastine) 0.05% ophthalmic solution Lastacaft (alcaftadine) 0.25% ophthalmic solution Optivar (azelastine) a 0.05% ophthalmic solution Patanol (olopatadine) a 0.1% ophthalmic solution Pataday (olopatadine) 0.2% ophthalmic solution Pazeo (olopatadine) 0.07% ophthalmic solution Prevention of itching associated with allergic Temporary relief of the signs and symptoms of allergic Prevention of itching associated with allergic Treatment of itching of the eye Treatment of the signs and symptoms of allergic Treatment of ocular itching Treatment of ocular itching One drop in each eye twice a day. One drop in the effected eye up to four times daily. Instill one drop in each eye once daily. One drop instilled into each affected eye twice a day. two times per day at an interval of 6 to 8 hours. once a day. once a day. CLINICAL RATIONALE An algorithm on treatment of allergic conjunctivitis (2013) uses a step wise approach, suggesting cold compresses, artificial tears, and OTC ophthalmic agents (e.g., pheniramine/naphazoline, ketotifen) as first line treatments for mild cases. Then if symptoms continue, or if OTC agents are not effective or not tolerated, prescription agents are recommended. Topical ophthalmic agents for the treatment of ocular allergy have a more rapid onset of action vs. oral antihistamines and are generally better tolerated. Topical antihistamines do not cause significant systemic side effects and generally do not contribute to ocular dryness. In clinical trials, dual-acting agents (e.g., ketotifen) have been shown to effectively reduce Choice_PS_Ophthalmic_Antihistamines_ST_ProgSum_0117_r0317_v2 Page 1 of 5
2 itching conjunctivitis with longer duration of effect and better tolerability than single-action antihistamines. 9 The American Academy of Asthma, Allergy, and Immunology (AAAI) states OTC antihistamine pills and eye drops are often used for short-term treatment of eye allergy symptoms. However, prolonged use of some eye drops may actually make symptoms worse. 10 For seasonal allergic conjunctivitis, the American Academy of Ophthalmology (AAO, 2013) suggests mild cases may be treated with an over-the-counter (OTC) antihistamine/vasoconstrictor (e.g., naphazoline/pheniramine), or with a more effective secondgeneration topical histamine H1-receptor antagonist (e.g., emedastine, alcaftadine). If the condition is frequently recurrent or persistent, mast cell stabilizers (e.g., cromolyn, lodoxamide, nedocromil) may be used to maintain comfort. Ophthalmic allergy preparations with dual antihistamine and mast-cell stabilizing properties, (e.g., ketotifen [OTC], azelastine, bepotastine, epinastine, olopatadine) may be used for either acute or chronic disease. There is no preference for one particular product in each class over the others. 11 Numerous comparative trials using allergic conjunctivitis agents have been conducted. From the results of the trials, it is difficult to declare one agent superior to another. 12,13,14 A meta-analysis of 8 studies compared the efficacy of the treatment of allergic conjunctivitis with topical antihistamines versus topical mast cell stabilizers, Results showed no significant differences being recorded in favor of any of the interventions. 15 Efficacy Alcaftadine 16 Fifty-eight subjects with a history of allergic conjunctivitis were enrolled in a double-masked, multicenter, vehicle-controlled study. Outcome measures were ocular itching and conjunctival redness. The signs and symptoms of allergic conjunctivitis were induced in the subjects by a conjunctival allergen challenge (CAC). The subjects were randomized to be given either one drop of alcaftadine 0.25% ophthalmic solution bilaterally or vehicle bilaterally. Alcaftadine significantly lessened conjunctival redness after both 15 minutes and 16 hours of the drug administration (p<0.001 vs. vehicle). Azelastine 5 In a conjunctival antigen challenge study, azelastine was more effective than vehicle in preventing itching In environmental studies, patients with seasonal allergic conjunctivitis were treated with azelastine or vehicle. In these studies azelastine was significantly more effective in relieving itching Bepotastine 17,18 Two Phase III, placebo-controlled, double-masked, randomized clinical trials in patients with allergic conjunctivitis assessed the efficacy of bepotastine besilate (BBOS) vs. placebo. The same study design was employed for both clinical trials, with subjects randomly assigned to either BBOS 1.5% (n=78) or placebo (n=79) treatment. Primary ocular end points included changes in ocular itching reported at 3, 5, and 7 minutes and conjunctival hyperemia assessed at 7, 15, and 20 minutes following each allergen challenge. Secondary ocular end points included chemosis as well as episcleral and ciliary hyperemia judged by investigators, and tearing (scored as either absent or present) and eyelid swelling judged by subjects. A statistically significant reduction in ocular itching was observed for BBOS 1.5% treatment compared to placebo at all time points (P<0.0001). Secondary end points were also significantly improved compared to placebo, most prominently for reduced tearing (no P value listed). Emedastine 19 Choice_PS_Ophthalmic_Antihistamines_ST_ProgSum_0117_r0317_v2 Page 2 of 5
3 Thirty-six subjects with allergic conjunctivitis were randomized into two groups in a doubleblind, single-center crossover study comparing emedastine 0.05% and ketorolac 0.5%. The first group received emedastine 0.05% in one eye and placebo in the other eye. The second group received ketorolac 0.5% in one eye and placebo in the other eye. Ten minutes after instillation, patients underwent allergen challenge. After the challenge, patients graded ocular itching and were assessed for hyperemia. Approximately 14 days later, subjects entered the crossover treatment phase. Emedastine 0.05% significantly inhibited ocular itching and redness (p<0.05). Epinastine 20 A prospective, single-center, randomized, double-masked, vehicle-controlled, Phase III clinical trial assessed the efficacy and tolerability of epinastine using the conjunctival antigen challenge in 67 patients with a history of allergic Patients were randomly assigned by eye to receive epinastine hydrochloride 0.05% ophthalmic solution in 1 eye and vehicle in the contralateral eye. Primary end points were ocular itching and conjunctival hyperemia. Itching was recorded 3, 5, and 10 minutes after antigen challenge. Hyperemia was recorded 5, 10, and 20 minutes after antigen challenge, as were secondary end points, which included eyelid swelling, episcleral and ciliary hyperemia, chemosis, tearing, and ocular mucous discharge. Mean severity scores for the following signs and symptoms were significantly lower with epinastine compared with vehicle at all time points after onset and duration challenges: ocular itching (P<0.001); eyelid swelling (P<0.001); conjunctival ( P<0.001), episcleral ( P<0.001), and ciliary hyperemia (P<0.001); and chemosis (P<or=0.009). Olopatadine Using the conjunctival an allergen challenge test, one dose of ophthalmic olopatadine 0.2% was comparable to two doses of ophthalmic olopatadine 0.1%, and both regimens were more effective than placebo in terms of mean itching scores in a small clinical trial. Olopatadine 0.7% was studied in two randomized, double-masked, placebo-controlled, conjunctival allergen challenge clinical studies. 21 Olopatadine 0.7% demonstrated statistically significantly improved relief of ocular itching compared to vehicle at minutes, 16 hours, and 24 hours after study treatment. Olopatadine 0.7% demonstrated statistically significantly improved relief of ocular itching compared to olopatadine 0.2% at 24 hours after study treatment, but not at minutes after study treatment. 8 Safety Common adverse effects of these agents include stinging and burning upon administration, eyelid edema and rhinitis. 22,23 Headache is also a common side effect with these agents. Of note, it occurs often in treatment with emedastine (11%), olopatadine (7%), bepotastine (2-5%), epinastine (1-3%), and azelastine (15%). 22 REFERENCES 1. Bepreve prescribing information. ISTA Pharmaceuticals, Inc. June Elestat prescribing information. Allergan, Inc. June Emadine prescribing information. Alcon Laboratories, Inc. May Lastacaft prescribing information. Allergan, Inc. December Optivar prescribing information. Meda Pharmaceuticals, Inc. July Patanol prescribing information. Alcon Laboratories, Inc. April Pataday prescribing information. Alcon Laboratories, Inc. December Pazeo prescribing information. Alcon Laboratories, Inc. January An algorithm for the management of allergic Allergy & Asthma Proceedings. 2013:34(5): Ocular symptoms, treatment and diagnosis. American Academy of Allergy, Asthma, and Immunology. (2014). Accessed 1/2/2015 at: Choice_PS_Ophthalmic_Antihistamines_ST_ProgSum_0117_r0317_v2 Page 3 of 5
4 11. Preferred Practice Pattern: Conjunctivitis. American Academy of Ophthalmology Accessed 1/2/2015 at: Multicenter Clinical Evaluation of Bepotastine Besilate Ophthalmic Solutions 1.0% and 1.5% to Treat Allergic Conjunctivitis. American Journal Ophthalmology. 2010; 150(1): e Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic Advances in Therapy. 2007:24(6): Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic Allergy & Asthma Proceedings. 2007:28(4): Topical treatments for seasonal allergic conjunctivitis: systematic review and metaanalysis of efficacy and effectiveness. British Journal General Practice. 2004;54: The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching Current Medical Research and Opinion. 2011:27(3): Bepotastine Besilate Ophthalmic Solutions Clinical Study Group Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clinical Therapy. 2009;31: Multicenter Clinical Evaluation of Bepotastine Besilate Ophthalmic Solutions 1.0% and 1.5% to Treat Allergic Conjunctivitis. American Journal of Ophthalmology. 2010;150: Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic Acta Ophthalmol Scand Suppl1; 228: Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic Clinical Therapy. 2004;26(1): Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clinical Therapy (8): Ocular comfort and drying effects of three topical antihistamine/mast cell stabilizers in adults with allergic conjunctivitis: a randomized, double-masked crossover study. Clinical Therapy. 2008; 30(7): Topical treatments for seasonal allergic conjunctivitis: systematic review and metaanalysis of efficacy and effectiveness. British Journal of General Practice 2004;54: Choice_PS_Ophthalmic_Antihistamines_ST_ProgSum_0117_r0317_v2 Page 4 of 5
5 Ophthalmic Antihistamine Step Therapy OBJECTIVE The intent of the Ophthalmic Antihistamine Step Therapy (ST) program is to encourage use of cost-effective generic products over the more expensive brand products. This program will accommodate for use of brand products when generic prerequisites cannot be used due to previous trial and failure; or the patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity. The program allows continuation of therapy when there is documentation that the patient is receiving the requested agent. Requests for brand products will be reviewed when patient-specific documentation is provided. TARGET DRUGS Bepreve (bepotastine) Elestat (epinastine) a Emadine (emedastine) Lastacaft (alcaftadine) Optivar (azelastine) a Patanol (olopatadine) a Pataday (olopatadine) Pazeo (olopatadine) a generic available PRI AUTHIZATION CRITERIA F APPROVAL Brand Ophthalmic Antihistamine will be approved when ONE of the following is met: 1. The patient s medication history indicates previous use of a generic ophthalmic antihistamine product in the past 90 days 2. There is documentation that the patient is currently using the requested agent 3. The prescriber states the patient is currently using the requested agent AND is at risk if therapy is changed 4. The patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to a generic ophthalmic antihistamine product Length of approval: 12 months Choice_PS_Ophthalmic_Antihistamines_ST_ProgSum_0117_r0317_v2 Page 5 of 5
Ophthalmic-1s: Antihistamine and Dual Acting Antihistamine/Mast Cell Stabilizers DHA Formulary Management Branch
May 2017 Antihistamine and Dual Acting Antihistamine/Mast Cell Stabilizers Executive Summary Page 1 of 5 Ophthalmic-1s: Antihistamine and Dual Acting Antihistamine/Mast Cell Stabilizers DHA Formulary Management
More informationRe-submission. Scottish Medicines Consortium. Olopatadine 1mg/ml eye drops, solution (Opatanol ) No. 59/03) Alcon Laboratories (UK) Ltd
Scottish Medicines Consortium Re-submission Olopatadine 1mg/ml eye drops, solution (Opatanol ) No. 59/03) Alcon Laboratories (UK) Ltd 9 December 2005 The Scottish Medicines Consortium (SMC) has completed
More informationGIVE THEM A DROP THAT LASTS Proven effective through 16 hours1-3
FOR PATIENTS WITH ITCHING DUE TO ALLERGIC CONJUNCTIVITIS INDICATIONS AND USAGE LASTACAFT (alcaftadine ophthalmic solution) 0.25% is an H1 histamine receptor antagonist indicated for the prevention of itching
More information12/3/2011. Disclosure. Allergic Eye Disease: Diagnostic Pearls and Treatment Options. Symptoms. Allergy Eye Disease
Disclosure Allergic Eye Disease: Diagnostic Pearls and Treatment Options I have no financial relationships to disclose. Ophthalmology Update 2011 Matilda Chan MD, PhD Department of Ophthalmology, UCSF
More informationKetotifen Fumarate and Olopatadine Hydrochloride in the Treatment of Allergic Conjunctivitis: A Real-World Comparison of Efficacy and Ocular Comfort
Advances In Therapy Volume 20 No. 2 March/April 2003 Ketotifen Fumarate and Olopatadine Hydrochloride in the Treatment of Allergic Conjunctivitis: A Real-World Comparison of Efficacy and Ocular Comfort
More informationCLINICAL SCIENCES. Efficacy of Ketotifen Fumarate 0.025% Ophthalmic Solution Compared With Placebo in the Conjunctival Allergen Challenge Model
CLINICAL SCIENCES Efficacy of Ketotifen Fumarate 0.025% Ophthalmic Solution Compared With Placebo in the Conjunctival Allergen Challenge Model Mark B. Abelson, MD; Matthew J. Chapin, BS; Barry M. Kapik,
More informationOCULAR ALLERGY IN CHILDREN. Presenter: Dr C.L.A Ogundo Consultant Ophthalmologist KPA conference April 2017
OCULAR ALLERGY IN CHILDREN Presenter: Dr C.L.A Ogundo Consultant Ophthalmologist KPA conference April 2017 Introduction Hypersensitivity disorder Conjunctival surface is accessible to allergens and is
More informationOphthalmic Immunomodulators Prior Authorization with Quantity Limit Program Summary
Ophthalmic Immunomodulators Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1,4 Agent Indication Dosage and Administration Restasis (cyclosporine ophthalmic emulsion)
More informationCONTRAINDICATIONS None.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PAZEO safely and effectively. See full prescribing information for PAZEO. PAZEO (olopatadine hydrochloride
More informationOcular Allergy. Phil Lieberman, MD
Ocular Allergy Phil Lieberman, MD Disclosure Consultant/Advisory Board: Genentech, Meda, Mylan, Teva Speaker: Genentech, Meda, Merck, Mylan, Teva Learning Objectives Upon completion of this session, participants
More informationNew Ways to Ease Allergy Symptoms
New Ways to Ease Allergy Symptoms New pharmacologic and immunotherapeutic agents may offer options for allergy sufferers. Michelle Stephenson, Contributing Editor 3/8/2012 Allergy season is quickly approaching,
More informationConjunctivitis - Allergic, Seasonal & Perennial (1 of 6) Patient presents w/ symptoms suggestive of allergic conjunctivitis
, Seasonal & Perennial ( of 6) A B Patient presents w/ symptoms suggestive of allergic conjunctivitis Non-pharmacological therapy 2 DIAGNOSIS Does the clinical presentation confirm seasonal or perennial
More informationCondition: Allergic Eye Disease (Type 1 Hypersensitivity reactions)
Condition: Allergic Eye Disease (Type 1 Hypersensitivity reactions) Description: Seasonal allergic conjunctivitis is caused by seasonal allergens, especially grass pollen, whereas perennial conjunctivitis
More informationTITLE: Olopatadine for the Treatment of Allergic Conjunctivitis: A Review of the Clinical Efficacy, Safety, and Cost-Effectiveness
TITLE: Olopatadine for the Treatment of Allergic Conjunctivitis: A Review of the Clinical Efficacy, Safety, and Cost-Effectiveness DATE: 23 March 2012 CONTEXT AND POLICY ISSUES Allergic conjunctivitis
More informationOcular Allergies: Scratching the Surface. -20%-50% of the population has allergies -83% of allergy sufferers experience ocular symptoms
How Many People Are Affected? Ocular Allergies: Scratching the Surface Mile Brujic, OD -20%-50% of the population has allergies -83% of allergy sufferers experience ocular symptoms Disclosure: I have no
More informationOral Agents. Formulary Limits. Available Strengths. IR: 4mg ER: 12mg Syrup: 2mg/5ml
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Seasonal Allergy Medications LAST REVIEW: 9/20/2016 THERAPEUTIC CLASS: Rheumatologic/Immunologic REVIEW HISTORY: 5/16, 5/15,
More informationA ntihistamine H1 blockers are a common first line
336 SCIENTIFIC REPORT Randomised double masked trial comparing the efficacy and tolerance of 0.05% mequitazine eye drops versus 0.05% levocabastine and placebo in allergic conjunctivitis induced by a conjunctival
More informationGrow Your Practice With a Focus on Ocular Allergy
By Scot Morris, O.D., F.A.A.O. Grow Your Practice With a Focus on Ocular Allergy Build your allergy patient base by making accurate diagnoses, offering the best treatments and increasing revenues with
More informationEfficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a doublemasked, environmental study of patient preference
CURRENT MEDICAL RESEARCH AND OPINION VOL. 20, NO. 7, 2004, 1167 1173 0300-7995 doi:10.1185/030079904125004321 2004 LIBRAPHARM LIMITED ORIGINAL ARTICLE Efficacy and comfort of olopatadine versus ketotifen
More informationProvided as a service by CiplaMed
Allergy Reaction of the body tissues to an allergen which leads to production of antibodies finally culminating in an antigen-antibody antibody reaction. Normal Individual Entry of allergen Allergen-Antibody
More informationSUBMISSION FOR RECLASSIFICATION OF MEDICINE. ZADITEN (KETOTIFEN 0.025% for Ophthalmic Use) TT , TT /1
SUBMISSION FOR RECLASSIFICATION OF MEDICINE ZADITEN (KETOTIFEN 0.025% for Ophthalmic Use) TT50-7009, TT50-7009/1 June 2008 PART A 1. International non-proprietary name Ketotifen 2. Proprietary name Zaditen
More informationInvestor Presentation December The vision to see past tomorrow
Investor Presentation December 2011 The vision to see past tomorrow Safe Harbor Statement Certain statements contained herein are forward-looking statements (as such term is defined in the Private Securities
More information3 DOSAGE FORMS AND STRENGTHS
PATADAY- olopatadine hydrochloride solution/ drops Alcon Laboratories, Inc. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PATADAY safely
More informationABSTRACT ORIGINAL RESEARCH. Atsuki Fukushima Nobuyuki Ebihara
Adv Ther (2014) 31:1045 1058 DOI 10.1007/s12325-014-0156-2 ORIGINAL RESEARCH Efficacy of Olopatadine versus Epinastine for Treating Allergic Conjunctivitis Caused by Japanese Cedar Pollen: A Double-Blind
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use epinastine hydrochloride ophthalmic solution safely and effectively. See full prescribing information
More informationTITLE: Olopatadine for the Treatment of Allergic Conjunctivitis: A Review of the Clinical Efficacy, Safety, and Cost-Effectiveness
TITLE: Olopatadine for the Treatment of Allergic Conjunctivitis: A Review of the Clinical Efficacy, Safety, and Cost-Effectiveness DATE: 17 March 2016 CONTEXT AND POLICY ISSUES Allergic conjunctivitis,
More informationPRODUCT INFORMATION NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. PATANOL * (Olopatadine) 0.1 % Eye Drops
PRODUCT INFORMATION PATANOL * (Olopatadine) 0.1 % Eye Drops NAME OF THE MEDICINE The active ingredient in PATANOL Eye Drops is olopatadine as its hydrochloride salt, or (Z)-11-[3-(dimethylamino)propylidene]-6-11-dihydrodibenz[b,e]oxepin-2-acetic
More informationUnderstanding and managing allergic conjunctivitis
Understanding and managing allergic conjunctivitis Mile Brujic, OD Ocular allergies are one of the most common conditions that doctors of optometry will treat in our practices. Although the prevalence
More informationNORTHEAST OHIO NEIGHBORHOOD HEALTH SERVICES, INC. OPTOMETRIC MEDICINE CLINICAL GUIDELINES: TABLE OF CONTENTS
NORTHEAST OHIO NEIGHBORHOOD HEALTH SERVICES, INC. OPTOMETRIC MEDICINE CLINICAL GUIDELINES: 2012-2013 TABLE OF CONTENTS CONDITION PAGE(S) Complete Eye and Vision Examination 2 Vision Screening Procedure
More informationPRODUCT MONOGRAPH PATANOL. Olopatadine Hydrochloride Ophthalmic Solution, 0.1% w/v (as olopatadine) Therapeutic Classification: Anti-allergy Agent
PRODUCT MONOGRAPH Pr PATANOL Olopatadine Hydrochloride Ophthalmic Solution, 0.1% w/v (as olopatadine) Therapeutic Classification: Anti-allergy Agent Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd.
More informationPRODUCT MONOGRAPH MINT-OLOPATADINE. Olopatadine Hydrochloride Ophthalmic Solution 0.1% w/v (as olopatadine) USP
PRODUCT MONOGRAPH Pr MINT-OLOPATADINE Olopatadine Hydrochloride Ophthalmic Solution 0.1% w/v (as olopatadine) USP Therapeutic Classification: Anti-allergy Agent Mint Pharmaceuticals Inc. 1093 Meyerside
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.
Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials The Harvard community has made this article openly
More informationTriage Information: 1. Duration of HPSJ Membership 2. Age 3. Fill history of Seasonal Allergy Medications
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Seasonal Allergy Medications LAST REVIEW: 5/28/2015 THERAPEUTIC CLASS: Rheumatologic/Immunologic REVIEW HISTORY: 5/15, 9/14
More informationEfficacy of 0.05% Cyclosporine A Eye Drops in Allergic Conjunctivitis in terms of Improvement in Ocular Itching Score
ORIGINAL ARTICLE Efficacy of 0.05% Cyclosporine A Eye Drops in Allergic Conjunctivitis in terms of Improvement in Ocular Itching Score 1 2 3 Muhammad Saleh Faisal, Kashif Ur Rehman Khalil, Mian Asim Shah
More informationSubmission to the. Medicines Classification Committee. for the Reclassification of Ketotifen from a. Prescription Medicine to a
Ketotifen (ophthalmic) Reclassification Page 1 of 11 Submission to the Medicines Classification Committee for the Reclassification of Ketotifen from a Prescription Medicine to a Pharmacy Only Medicine
More informationORIGINAL ARTICLE INTRODUCTION
Allergology International. ;:- ORIGINAL ARTICLE Efficacy of Hydrochloride Ophthalmic Suspension in the Conjunctival Allergen Challenge Test in Japanese Subjects with Seasonal Allergic Conjunctivitis Etsuko
More informationComments. Oral Antihistamines. Chronic Drug Treatments. Oral Allergy Medications
Comments: Even though OTC vasoconstrictors and antihistamines are popular, a recent article suggests that these drugs can cause rebound dilation of conjunctival vessels Chronic Drug Treatments Mast Cell
More informationODACTRA House Dust Mite (Dermatophagoides farina & Dermatophagoides pteronyssinus) allergen extract sublingual tablet
pteronyssinus) allergen extract sublingual tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan.
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zaditen 0.25 mg/ml, eye drops, solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains 0.345 mg ketotifen fumarate corresponding
More informationPage 1 RED EYES. conjunctivitis keratitis episcleritis / scleritis. Frank Larkin Moorfields Eye Hospital. acute glaucoma anterior uveitis
The RED EYE and ALLERGIC EYE DISEASE DIAGNOSIS & MANAGEMENT Frank Larkin Moorfields Eye Hospital RED EYES conjunctivitis keratitis episcleritis / scleritis acute glaucoma anterior uveitis post-op. / trauma
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
NEW ZEALAND DATA SHEET 1. PRODUCT NAME LOMIDE TM Lodoxamide trometamol 0.1% Eye Drops 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of Lomide Eye Drops contains the active ingredient lodoxamide trometamol
More informationDr Rachael Neiderer. Ophthalmologist Auckland. 8:35-8:50 Managing Allergic Conjunctivitis & Why Sodium Chromoglycate is Out
Dr Rachael Neiderer Ophthalmologist Auckland 8:35-8:50 Managing Allergic Conjunctivitis & Why Sodium Chromoglycate is Out Allergic conjunctivitis Rachael Niederer Greenlane Clinical Centre, Auckland Case
More informationVolume 4; Number 4 April 2010 PRESCRIBING GUIDANCE FOR HAY FEVER: SPRING / SUMMER 2010
Volume 4; Number 4 April 2010 PRESCRIBING GUIDANCE FOR HAY FEVER: SPRING / SUMMER 2010 PACEF Recommendations Recommended medicines remain the same as in recent years: Non-sedating antihistamines: generic
More informationPeople with eye allergies typically have symptoms that include: Eye Anatomy: What Do Eye Allergies Actually Effect?
Eye Allergies Eye Allergies People with eye allergies typically have symptoms that include: Itchy watery eyes Eyelid problems Dark circles around eyes Dry eyes Reactions to Contacts Let us help allow you
More informationTHE PEDIATRIC RED EYE (Handout)
THE PEDIATRIC RED EYE (Handout) Ida Chung, OD, MSHE, FCOVD, FAAO Western University College of Optometry Associate Professor/Assistant Dean of Learning 309 E. Second Street, Pomona, CA 91766 Office: 909-938-4140
More informationChemical Name: 4H-Pyrano[3,2-g]quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-, disodium salt.
ALCRIL (nedocromil sodium ophthalmic solution) 2% sterile DESCRIPTIN ALCRIL (nedocromil sodium ophthalmic solution) 2% is a clear, yellow, sterile solution for topical ophthalmic use. Nedocromil sodium
More informationInnovation In Ophthalmics
Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements
More informationIncrease Your Allergy Know How: A Review of the Latest Relevant Information on Ocular Allergy
CE LESSON Increase Your Allergy Know How: A Review of the Latest Relevant Information on Ocular Allergy RELEASE DATE: APRIL 2014 EXPIRATION DATE: MARCH 31, 2015 GOAL STATEMENT: Seasonal and perennial allergies
More informationAgenda. What s Up with OSD? 5/14/2015. OSD presents a significant challenge to physicians NEW CONCEPTS IN OCULAR SURFACE DISEASE
NEW CONCEPTS IN OCULAR SURFACE DISEASE Blair B Lonsberry, MS, OD, MEd., FAAO Diplomate, American Board of Optometry Professor of Optometry Pacific University College of Optometry blonsberry@pacificu.edu
More informationAllergy and inflammation
and inflammation 1 Allergic population hyper-producers of IgE consistently increasing western societies: ~20% of general population 2 Allergic population 3 Allergic triggers 4 Allergic triggers abnormal
More informationDrugs That May Be Used by Certain Optometrists
Drugs That May Be Used by Certain Optometrists Approved drugs. (a) Administration and prescription of pharmaceutical agents. Optometrists who are certified to prescribe and administer pharmaceutical agents
More informationThe allergic eye. Abstract. Introduction. Types of allergic conjunctivitis. Non-severe allergic conjunctivitis:
The allergic eye Andre Marais Senior lecturer and Clinical Pharmacologist Department of Pharmacology, School of Medicine, Faculty of Health Sciences, University of Pretoria, South Africa Correspondence
More informationPRODUCT MONOGRAPH. Pr PATADAY. Olopatadine Hydrochloride Ophthalmic Solution 0.2% w/v olopatadine (as olopatadine hydrochloride) Mfr. Std.
PRODUCT MONOGRAPH Pr PATADAY Olopatadine Hydrochloride Ophthalmic Solution 0.2% w/v olopatadine (as olopatadine hydrochloride) Mfr. Std. Anti-allergy Agent Novartis Pharmaceuticals Canada Inc. 385 Bouchard
More informationEvaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis
Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis Mark B. Abelson, MD, a'b Michelle A. George, BS, b Kendyl Schaefer,
More informationELESTAT- epinastine hydrochloride solution/ drops Allergan, Inc
ELESTAT- epinastine hydrochloride solution/ drops Allergan, Inc. ---------- HIGHLIGHT S OF PRESCRIBING INFORMAT ION These highlights do not include all the information needed to use ELESTAT safely and
More informationOverview & pathophysiology of Dry Eye and the use of cyclosporine eye drops in dry eye...
Overview & pathophysiology of Dry Eye and the use of cyclosporine eye drops in dry eye... This Allergan sponsored session was held on July 24, 2005, Hotel Satya Ashoka, Jabalpur. The session was followed
More informationInsomnia Agents (Sherwood Employer Group)
Insomnia Agents (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf Link to
More informationTopical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis (Review)
Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis (Review) Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A This is a reprint of
More informationAnterior Segment Ocular Allergy
Anterior Segment Ocular Allergy Topical Corticosteroids and Antihistamines Mast Cell Stabilizers for the Treatment of Allergic Conjunctivitis Lan Gong, MD, PhD 1 and Michael S Blaiss, MD 2 1. EYE and ENT
More information1/12/2017. Allergan Pharmaceuticals Speaker s Bureau Bio-Tissue BioDLogics, LLC Katena/IOP Seed Biotech Johnson and Johnson Vision Care, Inc.
Jeffrey R. Varanelli, OD, FAAO, Dipl ABO, ABCMO Nicholas Colatrella, OD, FAAO, Dipl AAO, ABO, ABCMO Allergan Pharmaceuticals Speaker s Bureau Bio-Tissue BioDLogics, LLC Katena/IOP Seed Biotech Johnson
More informationProduktinformationen för Bentifen, 0,25 mg/ml, Ögondroppar, lösning, endosbehållare, MTnr 16252, gäller vid det tillfälle då läkemedlet godkändes.
Produktinformationen för Bentifen, 0,25 mg/ml, Ögondroppar, lösning, endosbehållare, MTnr 16252, gäller vid det tillfälle då läkemedlet godkändes. Informationen kommer inte att uppdateras eftersom läkemedlet
More informationCommon Eye Problems. Claudia U. Richter, M.D. Ophthalmic Consultants of Boston, Inc.
Common Eye Problems for Subspecialists 2018 Claudia U. Richter, M.D. Ophthalmic Consultants of Boston, Inc. I have no financial disclosures to make. Goals of Course Evaluation and management of the red
More informationPRINCIPAL MEDICATION OPTIONS FOR RHINITIS
SEE INDICATED SUMMARY STATEMENT (SS#) DISCUSSION FOR SUPPORTING DATA ALLERGIC RHINITIS (AR): SEASONAL (SAR) AND PERENNIAL (PAR) MONOTHERAPY ORAL Antihistamines, oral (H1 receptor antagonists) (SS# 61-64)
More informationPhototherapy in Allergic Rhinitis
Phototherapy in Allergic Rhinitis Rhinology Chair KSU KAUH Ibrahim AlAwadh 18\1\2017 MBBS, SB & KSUF Resident, ORL-H&N Background: Endonasal phototherapy can relieve the symptoms of allergic rhinitis
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
RAGWITEK (Short Ragweed Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline
More informationEverant.in/index.php/jmpr. Journal of Medical Practice and Review
Everant.in/index.php/jmpr Journal of Medical Practice and Review Real world Efficacy and Tolerance of Bepotastine, a new 2 nd generation antihistamine, in Pruritis and other symptoms associated with cutaneous
More informationThe Medical Letter. on Drugs and Therapeutics. Drug Some Formulations OTC/Rx Usual Dosage Comments Class Comments Cost 1
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationThe allergic diseases that affect
TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS Jimmy D. Bartlett, OD, DSc Allergic conjunctivitis affects approximately 15% of the global population and has a higher prevalence of about 40% in industrialized
More informationSlide 4. Slide 5. Slide 6
Slide 1 Slide 4 Allergic Response Mechanisms of Type 1 hypersensitivity allergic reaction, IgE-mediated mast cell degranulation, and release of inflammatory mediators Antigen Derek N. Cunningham, O.D.,
More informationAnti-allergic ophthalmic drugs in general practice: which, why and when?
Anti-allergic ophthalmic drugs in general practice: which, why and when? Abstract Mohamed N, MBChB, FC Ophth(SA), Registrar; Smit DP, MBChB, MMed(Ophth), FCOphth(SA), Consultant Division of Ophthalmology,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPAINFUL PAINLESS Contact lens user BOV
Common Causes Allergies Infections Ocular Cornea, uveitis, endophthalmitis Orbital Orbital cellulitis Inflammation Uveitis Scleritis / episcleritis Glaucomas Trauma Foreign bodies Chemical injuries History
More informationPokharel S 1, Shah DN 2, Choudhary M 3 1 Lecturer Ophthalmology Department, KMC, Sinamangal, 2 Professor and 3 Lecturer, Ophthalmology Department,
Kathmandu University Medical Journal (2007), Vol. 5, No. 4, Issue 20, 526-530 Original Article Vernal keratoconjunctivitis: Modes of presentation in Nepalese population Pokharel S 1, Shah DN 2, Choudhary
More informationGlaucoma Disease Progression Role of Intra Ocular Pressure. Is Good Enough, Low Enough?
Glaucoma Disease Progression Role of Intra Ocular Pressure Is Good Enough, Low Enough? Glaucoma Diseases Progression Key Considerations Good number of patients may be diagnosed only after some damage the
More informationALLERGIC RHINITIS Eve Kerr, M.D., M.P.H.
- 63-3. ALLERGIC RHINITIS Eve Kerr, M.D., M.P.H. We conducted a MEDLINE search of review articles on rhinitis between the years of 1990-1995 and selected articles pertaining to allergic rhinitis. We also
More informationPREPARATION FOR ALLERGY TESTING *** Please read this information at least one week before your upcoming visit.
PREPARATION FOR ALLERGY TESTING *** Please read this information at least one week before your upcoming visit. In order to obtain valid and useful skin testing results, you will need to stop the use of
More informationEye Care Update Part II Ron Melton, OD, FAAO Randall Thomas, OD, MPH, FAAO
Eye Care Update Part II Ron Melton, OD, FAAO Randall Thomas, OD, MPH, FAAO www.eyeupdate.com Please silence all mobile devices and remove items from chairs so others can sit. Unauthorized recording of
More informationPharmacy Updates Summary
All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 4/16/2014 Effective date: 5/15/2014 Therapeutic Classes reviewed: ADHD Ophthalmic antihistamines
More informationINDICATIONS ACULAR 0,4% ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.
Page 1 SCHEDULING STATUS Schedule 4 PROPRIETARY NAME (and dosage form) ACULAR 0,4% COMPOSITION ACULAR 0,4% ophthalmic solution contains: Ketorolac tromethamine: 4 mg/ml Preservative: Benzalkonium chloride
More informationExpert Reviews on Ophthalmology. Treatment of Ocular Allergies: Non-pharmacologic, Pharmacologic and Immunotherapy
Expert Reviews on Ophthalmology Treatment of Ocular Allergies: Non-pharmacologic, Pharmacologic and Immunotherapy Dr Paramdeep S. Bilkhu, Dr Shehzad A. Naroo, Prof James S. Wolffsohn* Ophthalmic Research
More informationDEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code
More informationOcular allergy pathogenesis and diagnosis
Ocular allergy pathogenesis and diagnosis Luís Delgado, MD PhD departament of Immunology and Immunoallergology Unit Hospital de S. Joao. Porto (Portugal) Marzo 2006 www.alergomurcia.com Good morning, Mr.
More informationJagdeep Hundal, MD, Otolaryngology, Head & Neck Surgery 774 Christiana Rd, Suite B4, Newark, DE Phone: Fax:
Allergy Questionnaire Patient Name Date / / 1. What symptoms do you suffer from? Please circle below Eyes: Itchy eyes, tearing, eye redness, eye discharge Ears: Popping sensation, fullness, itching Nose/Sinus:
More informationKETOTIFEN OPHTHALMIC SOLUTION
PRODUCT MONOGRAPH Pr KETOTIFEN OPHTHALMIC SOLUTION Ketotifen Fumarate Ophthalmic Solution (0.25 mg/ml as Ketotifen) Anti-allergy Agent SteriMax Inc. 1-2735 Matheson Blvd E Mississauga, ON L4W 4M8 Date
More informationOcular itch associated with allergic conjunctivitis: latest evidence and clinical management
612745TAJ0010.1177/2040622315612745Therapeutic Advances in Chronic DiseaseS Ackerman, LM Smith review-article2016 Therapeutic Advances in Chronic Disease Review Ocular itch associated with allergic conjunctivitis:
More informationCourse # Eye Care Update 2018 Part I
Course # 100 Eye Care Update 2018 Part I DISCLOSURE STATEMENT Ron Melton and Randall Thomas are consultants to, on the speakers bureau of, on the advisory committee of, or involved in research for the
More informationPATIENT INFORMATION LEAFLET. PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM RELESTAT, epinastine hydrochloride 0,5 mg/ml, eye drops
Page 1 of 5 SCHEDULING STATUS Schedule 2 PATIENT INFORMATION LEAFLET PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM RELESTAT, epinastine hydrochloride 0,5 mg/ml, eye drops Read all of this leaflet
More informationPRODUCT INFORMATION. The chemical formula is C22H24OCIN 3.HCI and its molecular weight is It is presented as the racemate.
PRODUCT INFORMATION EYEZEP (azelastine hydrochloride) EYE DROPS 0.05% NAME OF THE DRUG EYEZEP eye drops contain 0.5 mg azelastine hydrochloride per ml (equivalent to 0.457 mg of azelastine base) as active
More informationMtM essentials for allergic rhinitis management
CREDIT: 2.0 Continuing Education EARN CE CREDIT FOR THIS ACTIVITY AT WWW.DRUGTOPICS.COM AN ONGOING CE PROGRAM OF THE UNIVERSITY OF CONNECTICUT SCHOOL OF PHARMACY AND DRUG TOPICS educational objectives
More informationNon-members present from Catamaran: Leslie Pittman, PharmD, Tracey Lovett, PharmD
TennCare Pharmacy Advisory Committee (PAC Meeting) February 12, 2013 Members in Attendance: Shana Bush, PharmD, Edward Capparelli, MD, Chairman Alan Corley, DPh, Stanley Dowell, MD, Co-Chairman Jeri Fitzpatrick,
More informationAzelastine nasal spray: the treatment of choice for allergic rhinitis
PRESS RELEASE Azelastine nasal spray: the treatment of choice for allergic rhinitis An astonishing one quarter of the planet s population suffers from allergic rhinitis, living with the aggravating symptoms
More informationALLERGIC RHINOSINUSITIS. Sirisha A Post graduate Dept of Pharmacology Kamineni Institute of Medical Sciences
ALLERGIC RHINOSINUSITIS Sirisha A Post graduate Dept of Pharmacology Kamineni Institute of Medical Sciences OVERVIEW Pathophysiology Goals of therapy Approaches to therapy Antihistaminics Corticosteroids
More informationItchy eyes a little irritation or a big pain
Itchy eyes a little irritation or a big pain Mrs Melanie Hingorani Consultant Ophthalmologist Moorfields Eye Hospital Declaration of any conflicts of interest None Allergic Eye Disease Group of disorders
More informationCase 1 61 year old female with 4 day history of am eyes being shut closed. Very itchy and sore. On Latanoprost OU. Vision no change.
Allergic Conjunctivitis: Current Trends and Advancements 2014 ASCRS JCAHPO Boston, MA., U.S.A. Saturday, April 26, 2014 Session A 3:30pm Dr. John T. Huang M.D., FRCSC, Dipl ABO Dr. Peter T. Huang M.D.,
More informationPRODUCT MONOGRAPH APO-OLOPATADINE. Olopatadine Hydrochloride Ophthalmic Solution USP. 0.2% w/v olopatadine (as olopatadine hydrochloride USP)
PRODUCT MONOGRAPH Pr APO-OLOPATADINE Olopatadine Hydrochloride Ophthalmic Solution USP 0.2% w/v olopatadine (as olopatadine hydrochloride USP) Anti-allergy Agent APOTEX INC. DATE OF REVISION: 150 Signet
More informationResearch Institute. Disclosures: Drs Danzig, Yao, and Staudinger are employees of Schering-Plough
A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber Friedrich Horak, MD* ; Petra Zieglmayer, MD*; René Zieglmayer, DI ; and
More informationAppendix 1 06/22/2017 BAP Meeting Private Citizen Comments Pfizer, Inc. submitted a written comment regarding the prior authorization criteria Eucrisa. The letter was presented to the Panel for review.
More informationBruce H. Koffler, M.D. Lindsay Koffler Cassidy, COT, OSC
Bruce H. Koffler, M.D. Lindsay Koffler Cassidy, COT, OSC Ocular surface disease patients can be very time consuming. You must have a streamlined system and work as a team in order to effectively run a
More informationEffect of Topical Cyclosporine 0.05% in Allergic Conjunctivitis
Effect of Topical Cyclosporine 0.05% in Allergic Conjunctivitis Delhi J Ophthalmol 2015; 25 (3): 171-175 DOI: http://dx.doi.org/10.7869/djo.101 * Sonali Bhalla, SK Sachan **, AM Jain ** * Bhalla Medical
More information